Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed

Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different ways to give a medication called terlipressin to patients with Acute on Chronic Liver Failure (ACLF) who are experiencing a severe bleeding problem known as esophageal variceal bleeding. The trial aims to find out whether a continuous infusion (a slow and steady delivery of the medicine) is more effective and safer than giving the medication in quick bursts (bolus). This is important because patients with ACLF who have this type of bleeding can face serious health risks, and finding the best treatment method could help improve their chances of recovery.

To be eligible for this trial, participants must be adults aged 18 or older who have been diagnosed with ACLF and are experiencing bleeding due to esophageal varices. However, individuals with certain conditions, including a history of heart disease, stroke, or other specific health issues, will not be able to join the study. Those who participate can expect to receive either form of terlipressin and will be monitored closely for any side effects or improvements in their condition. This research could provide valuable insights into better treatment options for patients facing this serious medical issue.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients (age ≥ 18 years) diagnosed with ACLF presenting with due to esophageal varices bleeding.
• Exclusion Criteria:
• • 1. Age \< 18 years
• • 2. History of coronary heart disease or ventricular arrhythmia,
• • 3. Stroke or transient ischemic attack,
• • 4. Bronchial asthma,
• • 5. Epilepsy,
• • 6. Pregnancy,
• • 7. Rebleeding.
• • 8. HCC
• • 9. Gastric variceal bleed